Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
27.53
+0.44 (1.62%)
Dec 20, 2024, 4:00 PM EST - Market closed
Castle Biosciences Employees
Castle Biosciences had 610 employees as of December 31, 2023. The number of employees increased by 67 or 12.34% compared to the previous year.
Employees
610
Change (1Y)
67
Growth (1Y)
12.34%
Revenue / Employee
$511,275
Profits / Employee
$9,959
Market Cap
771.04M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Avanos Medical | 3,771 |
agilon health | 1,117 |
Cytek Biosciences | 676 |
AbCellera Biologics | 586 |
Standard BioTools | 539 |
uniQure | 480 |
Cronos Group | 356 |
Tyra Biosciences | 49 |
CSTL News
- 2 days ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 9 days ago - Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma - Business Wire
- 4 weeks ago - Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 4 weeks ago - Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year - Business Wire
- 6 weeks ago - Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting - Business Wire
- 6 weeks ago - Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett's Esophagus Test - Business Wire
- 6 weeks ago - Use of Castle Biosciences' DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 - Business Wire
- 6 weeks ago - Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript - Seeking Alpha